A Clinical Trial to Evaluate INNA-051 as a Preventative Nasal Spray Treatment to Protect People from COVID-19 Infection and Prevent Transmission
Latest Information Update: 24 Dec 2020
At a glance
- Drugs INNA-051 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Ena Respiratory
- 17 Dec 2020 According to an Ena Respiratory media release, this trial is expected to begin by end of March 2021.
- 06 Oct 2020 New trial record
- 28 Sep 2020 According to an Ena Respiratory media release, Ena Respiratory has raised AU$11.7m from Australian investors and, subject to successful toxicity studies and regulatory approval, the company could be ready to test INNA-051 in human trials in less than four months.